Branded Legacy, Inc. Finalizes Transformative Acquisition of Bio Legacy Evaluative Group (f/k/a Menlo Health), Unlocking Explosive Growth Potential in Biotech and Drug Delivery

Core Insights - Branded Legacy, Inc. has completed the acquisition of Bio Legacy Evaluative Group, formerly Menlo Health, which positions the company to address global health challenges and enhance shareholder value through innovative technologies and strategic leadership [1][2][8] - The acquisition is expected to drive significant revenue growth, with projections indicating that Bio Legacy could generate up to $183.3 million in revenues by Year 5 [7] Acquisition Details - The acquisition agreement was executed on July 28, 2025, and closed on July 31, 2025, allowing Bio Legacy to operate as a wholly-owned subsidiary of Branded Legacy [5][8] - The deal involved an all-stock transaction valued at $1.5 million in Preferred D stock, aligning the interests of Bio Legacy with existing shareholders [5] Leadership and Vision - Amin Janmohamed has been appointed as CEO, and Dr. Kristian Thorlund as Chairman, bringing expertise to guide the company through its growth trajectory [3][8] - The leadership team is committed to long-term growth and innovation, focusing on delivering measurable results and substantial returns for shareholders [2][8] Product and Market Potential - Bio Legacy's patented intranasal naloxone device aims to address the addiction crisis, with the market expected to grow from $371 million in 2022 to over $1.16 billion by 2032, reflecting a CAGR of approximately 11.9% [4] - The company plans to expand its product offerings into vaccines and cold-chain therapies, tapping into significant untapped markets [4] Roadmap and Milestones - A robust R&D investment of $1 million is planned post-uplisting to OTCQB, with key milestones including manufacturing prototyping in Q3 2025, full patent filings in Q4 2025, and clinical trials in 2026 [6][5] - The naloxone device is set for market launch in Q1 2027, with expectations of substantial revenue contributions to Branded Legacy's portfolio [7]